PICO Portalanswers from OpenAlex & ORCID
Richard Greil
ResearcherPublications, citations & collaboration network
Richard Greil is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does Richard Greil have?
PICO Portalindexed works
Richard Greil has 1,411 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Richard Greil have?
PICO Portalcitation count
Richard Greil has 52,590 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of Richard Greil?
PICO Portalh-index
Richard Greil has an h-index of 104 in OpenAlex.
What is the i10-index of Richard Greil?
PICO Portali10-index
Richard Greil has an i10-index of 585 in OpenAlex.
What is the ORCID of Richard Greil?
PICO Portalorcid
The ORCID for Richard Greil is on the source record.
What is the OpenAlex record for Richard Greil?
PICO Portalopenalex
The OpenAlex for Richard Greil is on the source record.
What are the most-cited papers on Richard Greil?
PICO Portalmost cited works
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness, Kevin J. Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett Hughes, Ricard Mesı́a, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Ruey‐Long Hong, René González Mendoza, Ananya Roy, Yayan Zhang, Burak Gümüşçü, Jonathan D. Cheng, Fan Jin, Danny Rischin, Guillermo Lerzo, Marcelo Tatangelo, Mirta Varela, Juan José Zarbá, Michael Boyer, Hui Gan, Bo Gao, Brett Hughes, Girish Mallesara, Danny Rischin, Anne L. Taylor, Martin Burian, Thorsten Fuereder, Richard Greil, Carlos H. Barrios, Dalvaro Oliveira de Castro Junior, Gilberto de Castro, Fábio Franke, Gustavo Girotto, Iane Pinto Figueiredo Lima, Ulisses Ribaldo Nicolau, Gustavo Dix Junqueira Pinto, Lucas Vieira dos Santos, Ana-Paula Victorino, Neil Chua, Félix Couture, Richard Gregg, Aaron R. Hansen, John Hilton, Joy McCarthy, Denis Soulières, Rodrigo Ascuí, Pablo Gonzalez, Luis J. Villanueva-Rivera, Marco Torregroza, Ángela R. Zambrano, Petra Holečková, Zdeněk Král, Bohuslav Melichar, Prausova Jana, Milan Vošmik, Maria Andersen, Niels Gyldenkerne, Hannes Jürgens, Kadri Putnik, Petri Reinikainen, Viktor Gruenwald, Simon Laban, Gerasimos Aravantinos, Ioannis Boukovinas, Vassilis Georgoulias, Amanda Psyrri, D.L.W. Kwong, Yousuf Al-Farhat, Tibor Csőszi, József Erfán, Geza Horvai, László Landherr, Éva Remenár, Ágnes Ruzsa, Judit Szota, Salem Billan, Iris Gluck, Orit Gutfeld, Aron Popovtzer, Marco Benasso, Simona Bui, Vittorio Ferrari, Lisa Licitra, Franco Nolè, Takashi Fujii, Yasushi Fujimoto, Nobuhiro Hanai, Hiroki Hara, Koji Matsumoto, Kenji Mitsugi
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Rashmi K. Murthy, Sherene Loi, Alicia Okines, Elisavet Paplomata, Erika Hamilton, Sara A. Hurvitz, Nancy U. Lin, Virginia F. Borges, Vandana G. Abramson, Carey K. Anders, Philippe L. Bédard, Mafalda Oliveira, Erik Jakobsen, Thomas Bachelot, Shlomit Strulov Shachar, Volkmar Müller, Sofía Braga, François P. Duhoux, Richard Greil, David Cameron, Lisa A. Carey, Giuseppe Curigliano, Karen A. Gelmon, Gabriel N. Hortobágyi, Ian E. Krop, Sibylle Loibl, Mark D. Pegram, Dennis J. Slamon, Maria Corinna Palanca-Wessels, Luke Walker, Wentao Feng, Eric P. Winer
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors
Martin Filipits, Margaretha Rudas, R. Jakesz, Peter Dubsky, Florian Fitzal, Christian F. Singer, Otto Dietze, Richard Greil, Andrea Jelen, P. Sevelda, Christa Freibauer, Volkmar Müller, F. Jänicke, Marcus Schmidt, H. Kölbl, Achim Rody, Manfred Kaufmann, Werner Schroth, Hiltrud Brauch, Matthias Schwab, Péter Fritz, Karsten E. Weber, Inke Sabine Feder, Guido Hennig, Ralf Kronenwett, Mathias Gehrmann, Michael Gnant
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Vivek Subbiah, Ulrik Lassen, Elena Élez, Antoîne Italiano, Giuseppe Curigliano, Milind Javle, Filippo de Braud, Gerald W. Prager, Richard Greil, Alexander Stein, Angelica Fasolo, Jan H.M. Schellens, Patrick Y. Wen, Kert Viele, Aislyn Boran, Eduard Gasal, Paul Burgess, Palanichamy Ilankumaran, Zev A. Wainberg
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
Philippe Aftimos, Mafalda Oliveira, Alexandre Irrthum, Debora Fumagalli, Christos Sotiriou, Einav Nili Gal‐Yam, Mark E. Robson, Justin Ndozeng, Angelo Di Leo, Eva Ciruelos, Evandro de Azambuja, Giuseppe Viale, Elsemieke D. Scheepers, Giuseppe Curigliano, Judith M. Bliss, Jorge S. Reis‐Filho, Marco Colleoni, Marija Balić, Fátima Cardoso, Joan Albanell, Caroline Duhem, Sandrine Marréaud, Dario Romagnoli, Beatriz Rojas, Andrea Gombos, Hans Wildiers, Ángel Guerrero‐Zotano, Peter S Hall, Andrea Bonetti, Karolina Larsson, Martina Degiorgis, Silvia Khodaverdi, Richard Greil, Ásgerður Sverrisdóttir, Marta Paoli, Ethel Seyll, Sibylle Loibl, Barbro Linderholm, Gabriele Zoppoli, Nancy E. Davidson, Oskar T. Johannsson, Philippe L. Bédard, Sherene Loi, Susan Knox, David Cameron, Nadia Harbeck, Maite Lasa Montoya, Mariana Brandão, Andrea Vingiani, Carmela Caballero, Florentine Hilbers, Lucy Yates, Matteo Benelli, David Venet, Martine Piccart